4/A: Aquestive Therapeutics CEO Daniel Barber Amends Form 4 Filing to Correct Tax Withholding
SEC Form 4/A
Daniel Barber, CEO of Aquestive Therapeutics, amends his Form 4 filing to revise the number of shares withheld for tax obligations related to vested Restricted Stock Units.
Summary
- Daniel Barber, the President and CEO of Aquestive Therapeutics, filed an amended Form 4 with the SEC on October 2, 2024.
- The amendment corrects the number of shares withheld by Aquestive Therapeutics to satisfy Mr. Barber's tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
- On March 9, 2024, 56,824 shares of common stock were withheld at a price of $4.88 per share to cover these tax obligations.
- Following the transaction, Mr. Barber directly owns 826,478 shares of Aquestive Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing. The correction of the tax withholding information is a positive sign of attention to detail, but it doesn't represent a major event.
Industry Context
Form 4 filings are standard practice for company insiders to report changes in their beneficial ownership of company stock, providing transparency to investors.
Stakeholder Impact
- The correction of the tax withholding information ensures accurate reporting to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/09/2024 | Date of transaction where shares were withheld for tax obligations. |
| 03/12/2024 | Date of original Form 4 filing. |
| 10/02/2024 | Date of amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.